SEC Comment Letter 0000000000-24-005216 to Biofrontera Inc. (BFRI)
Biofrontera Inc.
Date: May 8, 2024 · CIK: 0001858685 · Accession: 0000000000-24-005216
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279090
Letter
United States securities and exchange commission logo May 8, 2024 Hermann Luebbert, Ph.D. Chairman and Chief Executive Officer Biofrontera Inc. 120 Presidential Way, Suite 330 Woburn, MA 01801 Re:Biofrontera Inc. Registration Statement on Form S-1 Filed May 3, 2024 File No. 333-279090 Dear Hermann Luebbert: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Andrew Terjesen, Esq.
Show Raw Text
United States securities and exchange commission logo
May 8, 2024
Hermann Luebbert, Ph.D.
Chairman and Chief Executive Officer
Biofrontera Inc.
120 Presidential Way, Suite 330
Woburn, MA 01801
Re:Biofrontera Inc.
Registration Statement on Form S-1
Filed May 3, 2024
File No. 333-279090
Dear Hermann Luebbert:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Andrew Terjesen, Esq.